Methadone Co-administration with Another Opioid – Co-analgesia – Low Dose

Co-administration: Definition

The term co-administration with another opioid was preferred to low-dose methadone, because methadone may also be used at low doses in opioid-naïve patients. It was also preferred to co-analgesia, which usually refers to the combination of several analgesic drugs and does not specifically describe the concomitant use of two opioids, one of which is methadone.

Co-administration consists of adding low-dose methadone, generally up to 30 mg/day, to another ongoing opioid treatment in order to improve pain control.

Rationale

This strategy is supported by methadone’s multiple mechanisms of action, including its NMDA receptor antagonist activity, in addition to its opioid effects.

Potential advantages

At low doses, adverse effects—particularly the risk of overdose—may be less pronounced than with full opioid rotation to methadone. ECG/QTc monitoring is recommended according to the product information at higher doses, particularly above 120 mg/day, whereas its systematic relevance at very low doses remains debatable.

Several studies have reported outpatient initiation of low-dose methadone.

How can it be introduced?

Most published studies report doses reaching approximately 10 mg/day within several days to a few weeks. Treatment should be initiated at a low dose and increased gradually, with close clinical monitoring and reassessment after every dose modification.

Examples of reported regimens include an

Initial dose ranging from 1 mg three times daily to 5 mg once daily,

followed, after approximately 1–2 weeks, by doses such as

3 mg three times daily or 10 mg once daily in the evening.

Limitations

Methadone co-administration does not currently have a specific marketing authorization for this indication, and large, high-quality clinical trials remain lacking

Hasegawa T, Okuyama T, Suzuki N, et al. Efficacy and safety of combining low-dose methadone with ongoing opioid treatment for uncontrolled cancer pain: an open-label single-arm study. The Oncologist. 2025;30(9):oyaf215. doi: 10.1093/oncolo/oyaf215.

Sato T, Fukutomi A, Kawamura T, Kawakami K, Sato T, Kamo Y, Suzuki T, Hagiya S, Tanaka R. Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients. Jpn J Clin Oncol. 2025;55(2):123-130. doi: 10.1093/jjco/hyae156.

Treillet E, Perceau-Chambard E, Economos G, et al. Low-dose methadone added to another opioid for cancer pain: a multicentre prospective study. Support Care Cancer. 2024;32:716. doi: 10.1007/s00520-024-08835-2. PMID: 39382714.

Duarte FCN, Ferraro LHDC, Ferreira A, Sakata RK. A randomized controlled trial evaluating the analgesic effect of the combination of methadone with morphine for cancer related pain. Clin J Pain. 2021;37(9):664-668. doi: 10.1097/AJP.0000000000000959. PMID: 34265791.

Chary S, Abdul-Razzak A, Galloway L. Ultralow-dose adjunctive methadone with slow titration, considering long half-life, for outpatients with cancer-related pain. Palliat Med Rep. 2020;1(1):119-123. doi: 10.1089/pmr.2020.0034. PMID: 34223466.

Fürst P, Lundström S, Klepstad P, Runesdotter S, Strang P. Improved pain control in terminally ill cancer patients by introducing low-dose oral methadone in addition to ongoing opioid treatment. J Palliat Med. 2018;21(2):177-181. doi: 10.1089/jpm.2017.0157. PMID: 28792784.

Courtemanche F, Dao D, Gagné F, Tremblay L, Néron A. Methadone as a coanalgesic for palliative care cancer patients. J Palliat Med. 2016;19(9):972-978. doi: 10.1089/jpm.2015.0525. PMID: 27399839.

Wallace E, Ridley J, Bryson J, Mak E, Zimmermann C. Addition of methadone to another opioid in the management of moderate to severe cancer pain: a case series. J Palliat Med. 2013;16(3):305-309. doi: 10.1089/jpm.2012.0335. PMID: 23391350.